An update from ConvaTec ( (GB:CTEC) ) is now available.
Convatec Group Plc announced the vesting of share awards for its CEO, Karim Bitar, under the company’s Long Term Incentive Plan and Deferred Bonus Plan. The shares were subsequently sold to cover tax and National Insurance liabilities. This transaction reflects the company’s ongoing commitment to aligning executive compensation with performance, potentially impacting stakeholder perceptions and reinforcing its market position.
More about ConvaTec
Convatec is a global medical products and technologies company that focuses on solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With a workforce of over 10,000 employees, Convatec operates in approximately 90 countries, offering products that enhance patient outcomes and reduce care costs. In 2024, the company’s revenues exceeded $2 billion, and it is a constituent of the FTSE 100 Index.
YTD Price Performance: 16.64%
Average Trading Volume: 5,438,993
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £5.21B
For an in-depth examination of CTEC stock, go to TipRanks’ Stock Analysis page.